Informed consent forms used for lung cancer trials are too long and complex for patients, according to research presented at the IASLC 2022 World Conference on Lung Cancer.
The research also suggests the layout of these forms can make it difficult for patients to find information they need, and the forms could be improved by a patient-centric addendum highlighting key points.